Halozyme Therapeutics, Inc. (HALO) stock
HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3037% above fair value
$95.80−0.17 (-0.18%)
Close on Nov 18, 2026Market cap $10.87BP/E 28.3Yield –
Halozyme Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Halozyme Therapeutics's total assets was $2.58B at Jun 30, 2026. For fiscal 2025 it was $2.53B, up 22.4% from the year before. Over ten years it grew 30.1% a year on average. The highest annual figure on record is $2.53B in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.53B | +22.4% |
| FY2024 | Dec 31, 2024 | $2.06B | +19.1% |
| FY2023 | Dec 31, 2023 | $1.73B | -5.9% |
| FY2022 | Dec 31, 2022 | $1.84B | +66.7% |
| FY2021 | Dec 31, 2021 | $1.10B | +90.4% |
| FY2020 | Dec 31, 2020 | $579.92M | +2.5% |
| FY2019 | Dec 31, 2019 | $565.87M | +28.5% |
| FY2018 | Dec 31, 2018 | $440.25M | -15.3% |
| FY2017 | Dec 31, 2017 | $519.95M | +98.8% |
| FY2016 | Dec 31, 2016 | $261.52M | +43.9% |
| FY2015 | Dec 31, 2015 | $181.79M | +9.5% |
| FY2014 | Dec 31, 2014 | $165.98M | +63.1% |
| FY2013 | Dec 31, 2013 | $101.79M | -24.4% |
| FY2012 | Dec 31, 2012 | $134.73M | +104.9% |
| FY2011 | Dec 31, 2011 | $65.76M | -28.0% |
| FY2010 | Dec 31, 2010 | $91.35M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.58B | +25.5% |
| Q1 FY2026 | Mar 31, 2026 | $2.67B | +21.7% |
| Q4 FY2025 | Dec 31, 2025 | $2.53B | +22.4% |
| Q3 FY2025 | Sep 30, 2025 | $2.22B | +4.9% |
| Q2 FY2025 | Jun 30, 2025 | $2.05B | +4.3% |
| Q1 FY2025 | Mar 31, 2025 | $2.20B | +19.3% |
| Q4 FY2024 | Dec 31, 2024 | $2.06B | +19.1% |
| Q3 FY2024 | Sep 30, 2024 | $2.12B | +11.9% |
| Q2 FY2024 | Jun 30, 2024 | $1.97B | +8.8% |
| Q1 FY2024 | Mar 31, 2024 | $1.84B | +8.4% |
| Q4 FY2023 | Dec 31, 2023 | $1.73B | -5.9% |
| Q3 FY2023 | Sep 30, 2023 | $1.89B | +1.5% |
| Q2 FY2023 | Jun 30, 2023 | $1.81B | +1.6% |
| Q1 FY2023 | Mar 31, 2023 | $1.70B | +46.2% |
| Q4 FY2022 | Dec 31, 2022 | $1.84B | +66.7% |
| Q3 FY2022 | Sep 30, 2022 | $1.86B | +57.3% |
| Q2 FY2022 | Jun 30, 2022 | $1.78B | +73.6% |
| Q1 FY2022 | Mar 31, 2022 | $1.16B | +20.2% |
| Q4 FY2021 | Dec 31, 2021 | $1.10B | +90.4% |
| Q3 FY2021 | Sep 30, 2021 | $1.19B | +126.2% |
| Q2 FY2021 | Jun 30, 2021 | $1.03B | +94.7% |
| Q1 FY2021 | Mar 31, 2021 | $966.58M | +96.3% |
| Q4 FY2020 | Dec 31, 2020 | $579.92M | +2.5% |
| Q3 FY2020 | Sep 30, 2020 | $524.03M | +41.5% |
| Q2 FY2020 | Jun 30, 2020 | $527.00M | +26.1% |
| Q1 FY2020 | Mar 31, 2020 | $492.35M | +14.7% |
| Q4 FY2019 | Dec 31, 2019 | $565.87M | +28.5% |
| Q3 FY2019 | Sep 30, 2019 | $370.36M | -16.7% |
| Q2 FY2019 | Jun 30, 2019 | $417.83M | -12.0% |
| Q1 FY2019 | Mar 31, 2019 | $429.11M | -13.4% |
| Q4 FY2018 | Dec 31, 2018 | $440.25M | -15.3% |
| Q3 FY2018 | Sep 30, 2018 | $444.51M | +24.5% |
| Q2 FY2018 | Jun 30, 2018 | $474.75M | +37.7% |
| Q1 FY2018 | Mar 31, 2018 | $495.47M | +118.5% |
| Q4 FY2017 | Dec 31, 2017 | $519.95M | +98.8% |
| Q3 FY2017 | Sep 30, 2017 | $357.15M | +26.4% |
| Q2 FY2017 | Jun 30, 2017 | $344.79M | – |
| Q1 FY2017 | Mar 31, 2017 | $226.77M | – |
| Q4 FY2016 | Dec 31, 2016 | $261.52M | – |
| Q3 FY2016 | Sep 30, 2016 | $282.50M | – |
See a number that looks wrong?